|
Date: 19 Jan 2021
Time: 11am - 12pm Format: Webinar (registration is required) Hosted by: Adrian TEO, IMCB & ExCo SCSS |
|
Speaker's information
Prof Dean HO Provost’s Chair Professor of Biomedical Engineering and Pharmacology National University Singapore Harnessing Digital Medicine to Optimise Drug Development and N-of-1 Healthcare |
|
ABSTRACT
In the quest for truly optimised medicine, multiple challenges need to be overcome - The right drugs and corresponding doses need to be identified, which can be insurmountable given the very large parameter space created. In addition, a one-size-fits-all approach serves as a barrier to individualising treatment, as even effective drugs given at incorrect dosages can result in little to no efficacy. Furthermore, these doses may need to be modulated dynamically during the course treatment, since the patient response to treatment can also be dynamic. We will discuss our recent advances in clinical trials innovation and the clearance of first-in-class patient studies, as well as results from our ongoing clinical development studies. The ultimate objectives of WisDM and N.1, which are already being observed in the clinic, are to dynamically tailor patient-specific treatment outcomes, reduce healthcare costs, and increase accessibility to practice-changing and optimised medicine.
BIO
Prof. Dean Ho is Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore. Using his CURATE.AI platform, Prof. Ho has led multiple pioneering clinical studies that have validated the promise of N-of-1 medicine, where only a patient’s own data is used to personalise their treatment. Prof. Ho is an elected member of the US National Academy of Inventors (NAI and Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Fulbright Scholar. Prof. Ho appeared on the National Geographic Channel and his discoveries were featured on CNN, The Economist, Forbes, NPR and other news outlets. He served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member global drug development organization
In the quest for truly optimised medicine, multiple challenges need to be overcome - The right drugs and corresponding doses need to be identified, which can be insurmountable given the very large parameter space created. In addition, a one-size-fits-all approach serves as a barrier to individualising treatment, as even effective drugs given at incorrect dosages can result in little to no efficacy. Furthermore, these doses may need to be modulated dynamically during the course treatment, since the patient response to treatment can also be dynamic. We will discuss our recent advances in clinical trials innovation and the clearance of first-in-class patient studies, as well as results from our ongoing clinical development studies. The ultimate objectives of WisDM and N.1, which are already being observed in the clinic, are to dynamically tailor patient-specific treatment outcomes, reduce healthcare costs, and increase accessibility to practice-changing and optimised medicine.
BIO
Prof. Dean Ho is Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore. Using his CURATE.AI platform, Prof. Ho has led multiple pioneering clinical studies that have validated the promise of N-of-1 medicine, where only a patient’s own data is used to personalise their treatment. Prof. Ho is an elected member of the US National Academy of Inventors (NAI and Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Fulbright Scholar. Prof. Ho appeared on the National Geographic Channel and his discoveries were featured on CNN, The Economist, Forbes, NPR and other news outlets. He served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member global drug development organization